Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.
In comparison, peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Intuitive Surgical (ISRG) have mean ratings of 1.8, 2.32, and 2.06, respectively. Their target prices are $78.65, $161.20, and $578.07, respectively.
After a strong run from $20.25 on April 9 to a high of $53.70 on October 1, NovoCure stock has experienced selling pressure in October. It corrected to $43.87 on October 11. In the past week, it managed to recover to $46.50.
The enterprise value of NovoCure is $4.03 billion, and its enterprise-value-to-revenue ratio is 18.53x. Its price-to-sales and price-to-book ratios are 19.33x and 37.48x, respectively.
NovoCure’s current ratio, a metric of how effectively a company can meet its short-term obligations, is 6.40x. In comparison, the current ratios of Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Intuitive Surgical (ISRG) are 1.6x, 2.3x, and 6.0x, respectively.